Progress Your Preclinical Research with Our Validated In Vivo Models
Our clients consistently use our comprehensive suite of validated Translational In Vivo Platforms to advance their preclinical development programs in a timely and cost-effective manner.
We work with you to help you choose the most appropriate platform, study design, and screening method matched to each individual drug candidate.
CrownBio has established multiple in vivo assay systems to evaluate novel anticancer compounds. Each assay is designed to understand specific aspects of each drug property and its mechanism of action. Our platforms include:
- Over 200 ValidatedXeno™ Cell Line Derived Xenograft models
- PDX tumor-derived xenograft models (PrimeXeno™)
- Nude rat models
- Bioluminescent models for optical imaging
- A wide range of specialty models
Improved preclinical immuno-oncology models are needed to drive forward research in this fast paced field. CrownBio provides a wide ranging In Vivo Immunotherapy Translational Technology Platform including specific models:
- For evaluation of CAR-T therapies
- Stable and transient humanized models including
PDX models provide a more predictive alternative for preclinical drug evaluation. CrownBio has developed HuPrime® the largest commercial collection of PDX models, complemented by our HuKemia® patient-derived blood cancer models.
Our models and Translational Oncology Platforms help pharmaceutical companies:
- Prioritize lead compounds
- Narrow down possible disease indication
- Identify biomarkers to stratify patient populations in clinical trials
therefore lowering drug attrition rate and reducing development costs.
Our immunotherapy platform also includes our large suite of syngeneic tumor models. Our models are fully validated and immunoprofiled, with checkpoint inhibitor benchmarking data available.
Ready for use for single agent and combination immunotherapy evaluation, our syngeneic models are also utilized in MuScreen™ the first large-scale, staggered, in vivo screening platform for cancer immunotherapeutics.